Large Liver Mass Found in 53-Year-Old Man

Poll

A 53-year-old man presents with a large hepatic mass. After further evaluation, a biopsy is performed. What is your diagnosis?

A 53-year-old man presents with a large hepatic mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Hepatic adenoma
B. Intrahepatic cholangiocarcinoma
C. Biliary cirrhosis
D. Bile duct adenoma
Recent Videos
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer

Roman Fabbricatore
March 23rd 2025
Article

Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer

Russ Conroy
March 17th 2025
Article

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

Russ Conroy
March 7th 2025
Article

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer

Roman Fabbricatore
March 5th 2025
Article

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.

Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer

Roman Fabbricatore
January 27th 2025
Article

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.